UNITO-001- Study in HRR/PDL1 Positive MPM/NSCLC

Summary

This is a single arm, prospective, interventional, multicenter phase 2 study of the combination of niraparib and dostarlimab in patients with advanced non-small cell lung cancer (NSCLC) and/or malignant pleural mesothelioma (MPM), and positive for PD-L1 expression (TPS ≥ 1%) and germline or somatic mutations in the DNA homologous recombination repair (HRR) genes.

Timeline

Start

2020-12-23

Primary completion

2024-06-30

Completion

2025-06-30

Drugs

Indications